Pfizer’s Wyeth sues Novartis’ Sandoz over breast cancer drug patent
16-11-2021
Delhi court approves Natco generic of Novartis cancer drug
29-08-2019
16-12-2021
Pavel Kapysh / Shutterstock.com
Public biopharmaceutical company NextCure has been accused of misappropriating trade secrets in order to create a direct competitor to a biotech’s cancer immunotherapy technology.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
Start a subscription today to access the LSIPR website
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at achoudhury@newtonmedia.co.uk
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
NextCure, Eli Lilly, Immunaccel, cancer treatment, immunotherapy